Cd16 - Open Access .click

Results 261 to 270 of about 98,093 (297)

Some of the next articles are maybe not open access.

Soluble CD16 in the Treatment of Murine Lupus Nephritis

Clinical Immunology and Immunopathology, 1998
To determine if soluble CD16 (sCD16) could alter the expression of lupus-like disease, groups of 10 female NZB/NZW mice (age 16-20 weeks) were given sCD16 three times a week for 5 weeks (control; 100 microg; 200 microg/dose) after onset of proteinuria.
H, Watanabe, D, Sherris, G S, Gilkeson
openaire +2 more sources

Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis

Molecular Immunology, 1999
Bispecific antibody (bsAb)-based clinical trials of cancer have been conducted primarily using intact murine monoclonal antibody (mAb)-derived molecules. In some of these trials, toxicity resulting from the interactions of antibody Fc domains with cellular Fc receptors has limited the doses of antibody (Ab) that can be employed. Furthermore, human anti-
A M, McCall +9 more
openaire +2 more sources

Prevalence of classical CD14++/CD16 − but not of intermediate CD14++/CD16 + monocytes in hypoalphalipoproteinemia